Premium
Treatment of varicella‐zoster virus and postherpetic neuralgia
Author(s) -
Carrasco Daniel A.,
Straten Melody Vander,
Tyring Stephen K.
Publication year - 2000
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1046/j.1529-8019.2000.00027.x
Subject(s) - postherpetic neuralgia , medicine , shingles , chickenpox , varicella zoster virus , neuralgia , dermatology , virus , anesthesia , virology , neuropathic pain
Chickenpox is mostly a disease of childhood; shingles usually affects the elderly, but any age group may be afflicted. Although several proved pharmacologic agents are known to be efficacious in the acute phase of varicella‐zoster infections, only three are FDA approved for use in immunocompetent zoster patients and one for the use in primary varicella infections. Ongoing studies with immunocompromised patients are determining whether higher doses of newer oral antivirals will be effective. While a cure for postherpetic neuralgia has not been found, effective treatment to reduce its duration and severity means early implementation of newer antiviral agents. While corticosteroids do not prevent postherpetic neuralgia, they do improve the quality of life when used in combination with acyclovir. Often, symptomatic relief with narcotics, topical anesthetics, and tricyclic antidepressants are necessary.